Effects of Renal Impairment on the Pharmacokinetics of Once-Daily Amantadine Extended-Release Tablets

BACKGROUND: An extended-release formulation of amantadine (Osmolex ER™, Osmotica Pharmaceutical US LLC) was approved in February 2018 to treat Parkinson’s disease and drug-induced extrapyramidal reactions in adults. OBJECTIVES: To determine the pharmacokinetic profile of extended-release amantadine...

Descripción completa

Detalles Bibliográficos
Autores principales: deVries, Tina, Dentiste, Angela, Di Lea, Clifford, Pichette, Vincent, Jacobs, David
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2019
Materias:
Original Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6669187/
https://www.ncbi.nlm.nih.gov/pubmed/31342404
http://dx.doi.org/10.1007/s40263-019-00651-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6669187/
https://www.ncbi.nlm.nih.gov/pubmed/31342404
http://dx.doi.org/10.1007/s40263-019-00651-1

Ejemplares similares